What question did this study set out to answer?

The aim is to explore YB-1's role in DNA damage response and its influence on tumor immune interactions.

April 27, 2026JNCI Cancer Spectrum0 citationsOpen Access

Y-box Binding Protein-1 at the Crossroads of DNA Damage Response and Tumor Immune Evasion

MTMahmoud ToulanyUniversity of Wisconsin–Madison QSQuaovi H. SodjiUniversity of Wisconsin–Madison

Key Points

The aim is to explore YB-1's role in DNA damage response and its influence on tumor immune interactions.
Critical review of existing literature on YB-1 and its functions in the tumor microenvironment and immune modulation.
Analysis of YB-1's impact on DNA damage response signaling and immune evasion mechanisms.
YB-1 enhances the activation of DNA damage response following radiotherapy.
It regulates cytokine production and alters immune checkpoint expression, facilitating immune evasion.
YB-1's role may provide insights for developing new therapeutic strategies in cancer immunotherapy.

Abstract

Tumor response to radiotherapy is shaped by multiple factors including immune modulation, tumor microenvironment and genetic factors. Among these, the Y-box binding protein-1 (YB-1) is a multifunctional DNA/RNA-binding protein frequently overexpressed in tumors. YB-1 controls the activation of DNA damage response (DDR) signaling following radiotherapy. Emerging evidence suggests that the role of YB-1 extends beyond DDR regulation to shaping tumor-immune interactions by regulating cytokine production, promoting immune evasion, and altering immune checkpoint expression. Elucidating these immune-related functions of YB-1 may uncover novel mechanisms of tumor immune evasion and identify novel therapeutic targets to enhance cancer immunotherapy. This mini-review summarizes current insights into the role of YB-1 in immune regulation, highlighting its impact on tumor immunity and potential clinical applications.

Ask AI

Helpful

Bookmark

View Full Paper